|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0085533,
umls-concept:C0282461,
umls-concept:C0392920,
umls-concept:C0439231,
umls-concept:C0439743,
umls-concept:C0728747,
umls-concept:C1446409
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-10-27
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adjuvant therapy for patients with HER2-overexpressing breast tumors. The Short-HER study is a phase III randomized, multicentric Italian trial aimed at testing the optimal duration of adjuvant trastuzumab. In this trial, 2500 patients with HER2-positive breast cancer will be randomized to receive the following: (arm A, long) 4 courses of anthracycline- based chemotherapy (doxorubicin/cyclophosphamide or epidoxorubicin/cyclophosphamide) followed by 4 courses of docetaxel or paclitaxel in combination with trastuzumab, followed by 14 additional courses of trastuzumab administered every 3 weeks (for a total of 18 3-weekly doses of trastuzumab); or (arm B, short) 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab (for a total of 9 weekly doses of trastuzumab) followed by 3 courses of 5-fluorouracil/epirubicin/cyclophosphamide. The primary objective is disease-free survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1526-8209
|
|
pubmed:author |
pubmed-author:AgostaraBiagioB,
pubmed-author:BelfiglioMaurizioM,
pubmed-author:BertettoOscarO,
pubmed-author:BruzziPaoloP,
pubmed-author:CascinuStefanoS,
pubmed-author:CognettiFrancescoF,
pubmed-author:ContePierFrancoP,
pubmed-author:CrinóLucioL,
pubmed-author:D'AmicoRobertoR,
pubmed-author:Di LeoAngeloA,
pubmed-author:FrassoldatiAntonioA,
pubmed-author:GuarneriValentinaV,
pubmed-author:MolinoAnnamariaA,
pubmed-author:PronzatoPaoloP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
453-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18952561-Antibodies, Monoclonal,
pubmed-meshheading:18952561-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18952561-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18952561-Breast Neoplasms,
pubmed-meshheading:18952561-Chemotherapy, Adjuvant,
pubmed-meshheading:18952561-Cyclophosphamide,
pubmed-meshheading:18952561-Disease-Free Survival,
pubmed-meshheading:18952561-Doxorubicin,
pubmed-meshheading:18952561-Epirubicin,
pubmed-meshheading:18952561-Female,
pubmed-meshheading:18952561-Fluorouracil,
pubmed-meshheading:18952561-Humans,
pubmed-meshheading:18952561-Paclitaxel,
pubmed-meshheading:18952561-Receptor, erbB-2,
pubmed-meshheading:18952561-Research Design,
pubmed-meshheading:18952561-Taxoids
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
|
|
pubmed:affiliation |
Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, Modena, Italy.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
